A Randomized, Partially Blinded, 4-period, Crossover Study to Assess the Effects of Single-dose AEB071 Administration (300 and 900 mg) on Electrocardiographic QT Intervals Compared to Placebo in Healthy Volunteers

Trial Profile

A Randomized, Partially Blinded, 4-period, Crossover Study to Assess the Effects of Single-dose AEB071 Administration (300 and 900 mg) on Electrocardiographic QT Intervals Compared to Placebo in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 15 May 2012

At a glance

  • Drugs Moxifloxacin; Sotrastaurin
  • Indications B cell lymphoma; Bacterial infections; Liver transplant rejection; Psoriasis; Renal transplant rejection; Ulcerative colitis; Uveal melanoma; Uveitis
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 15 May 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top